Patients undergoing treatments targeting Mcl-1 could be more susceptible to severe RSV and influenza infection or other respiratory pathogens, due to the virus being able to replicate uncontrolled when Mcl-1 is suppressed. The gene discussed is MCL1; the disease is influenza.